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Abstract
Background: In a previous study, we showed that consumption of diets enriched in saturated fatty acids causes
changes in alternative splicing of pre-mRNAs encoding a number of proteins in rat skeletal muscle, including the one
encoding skeletal muscle Troponin T (Tnnt3). However, whether saturated fatty acids act directly on muscle cells to
modulate alternative pre-mRNA splicing was not assessed. Moreover, the signaling pathway through which saturated
fatty acids act to promote changes in alternative splicing is unknown. Therefore, the objective of the present study was
to characterize the signaling pathway through which saturated fatty acids act to modulate Tnnt3 alternative splicing.
Methods: The effects of treatment of L6 myotubes with saturated (palmitate), mono- (oleate), or polyunsaturated
(linoleate) fatty acids on alternative splicing of pre-mRNA was assessed using Tnnt3 as a marker gene.
Results: Palmitate treatment caused a two-fold change (p< 0.05) in L6 myotube Tnnt3 alternative splicing whereas
treatment with either oleate or linoleate had minimal effects compared to control myotubes. Treatment with a
downstream metabolite of palmitate, ceramide, had effects similar to palmitate on Tnnt3 alternative splicing and inhibition
of de novo ceramide biosynthesis blocked the palmitate-induced alternative splicing changes. The effects of palmitate and
ceramide on Tnnt3 alternative splicing were accompanied by a 40–50% reduction in phosphorylation of Akt on S473.
However, inhibition of de novo ceramide biosynthesis did not prevent palmitate-induced Akt dephosphorylation,
suggesting that palmitate may act in an Akt-independent manner to modulate Tnnt3 alternative splicing. Instead,
pre-treatment with okadaic acid at concentrations that selectively inhibit protein phosphatase 2A (PP2A) blocked both
palmitate- and ceramide-induced changes in Tnnt3 alternative splicing, suggesting that palmitate and ceramide act
through PP2A to modulate Tnnt3 alternative splicing.
Conclusions: Overall, the data show that fatty acid saturation level and ceramides are important factors modulating
alternative pre-mRNA splicing through activation of PP2A.
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Introduction
Alternative splicing is a critical step in the processing of
precursor mRNA (pre-mRNA) into mature mRNA that
involves the selective removal of exons from a pre-mRNA.
Alternative splicing can generate multiple mature mRNAs
from a single gene thus allowing for a significant expan-
sion of the transcriptome and a concomitant increase in
proteome plasticity and functionality [1]. The regulation
of alternative splicing is complex. In brief, it involves the
dynamic interplay of cis- and trans-acting factors to
coordinate the placement of the spliceosome, a large
macromolecular complex responsible for the catalytic re-
moval of introns and exons, onto a pre-mRNA [2–6].
Cis-acting factors are RNA sequence elements and thus
are inherent to the pre-mRNA [7, 8], whereas trans-acting
factors are splicing accessory proteins that bind cis-factors
to facilitate splice site recognition [6, 9, 10]. In addition to
being regulated through transcriptional mechanisms,
trans-acting factors are also post-translationally modified
by kinases and phosphatases [11, 12]. Thus, the
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phosphorylation state of components of the splicing regu-
latory machinery is a critical determinant of whether or
not an alternatively spliced exon is included in or excluded
from a mature RNA.
One of the best characterized examples of phosphoryla-
tion-mediated regulation of alternative splicing is through
the Akt signaling axis. Indeed, several trans-acting factors
(i.e. serine-arginine-rich (SR) proteins and SR protein
kinases) involved in pre-mRNA alternative splicing are
substrates of Akt [4, 11–14]. The contribution of protein
phosphatases (PP) to changes in trans-acting factor phos-
phorylation is less well studied. Protein phosphatases
(PP)1 and 2A are required for the proper assembly and
disassembly of spliceosomal components [15] and regulate
alternative splicing by directly targeting trans-acting
proteins or indirectly by modulating Akt phosphorylation
[16, 17].
Troponin is a heterotrimeric complex that mediates
calcium-induced sarcomere contraction [18]. The tropo-
nin T subunit links the calcium binding subunit,
troponin C, to tropomyosin, and therefore plays a crit-
ical role in calcium signaling to the sarcomere. We
recently demonstrated that fast skeletal muscle troponin
T (Tnnt3) pre-mRNA is alternatively spliced in rat
gastrocnemius muscle in response to consumption of a
high-fat diet prior to the onset of obesity. Interestingly,
this effect was specific to diets enriched in lard, as diets
enriched in mono- or polyunsaturated fatty acids had no
effect on Tnnt3 alternative splicing [19]. A major differ-
ence between the three diets used in that study was the
proportion of the saturated fat, palmitate, in the
lard-enriched diet. Palmitate is a substrate commonly
used in the biosynthesis of ceramides [20, 21], a family
of sphingolipid second messengers that are induced in
response to a variety of cellular stressors [22–24]. The
above observations suggest that the diet-specific effects
on Tnnt3 pre-mRNA alternative splicing are caused by
specific types of fatty acids in the high-fat lard diet and/
or the intramuscular accumulation of ceramides. There
is some precedent for this hypothesis, as previous work
demonstrated that PP1 is necessary for the ceramide-
induced changes in the alternative splicing of Bcl-xL and
caspase-9 pre-mRNAs [24]. Other studies have reported
diet- or obesity-induced changes in pre-mRNA alterna-
tive splicing [25–34], but little is known about the role
of specific fatty acids in this process.
Though it is tempting to speculate that changes in
skeletal muscle alternative splicing in the aforemen-
tioned studies were due to the accumulation of fatty acids
or ceramides, hormonal feedback mechanisms control-
ling metabolic status complicate delineating mechanisms
that modulate alternative splicing in vivo [1, 35]. Hence,
we employed an in vitro system to precisely control the
exposure of muscle cells to fatty acids and ceramides to
examine the effects on alternative splicing and potential
signaling pathways involved in regulating this process.
Therefore, using Tnnt3 as a marker gene in L6 myotubes
we hypothesized that treatment with saturated fatty
acids and ceramides would alter the pattern of alterna-
tive splicing while unsaturated fatty acids would have
little to no effect.
Methods
Fatty acid/BSA conjugation
Palmitate, oleate, or linoleate (Sigma, St. Louis, MO)
were dissolved in glass vials at 70 °C in a 50% Ethanol/
Dulbecco’s phosphate buffered saline (DPBS) (Gibco,
Thermo Fisher, Waltham, MA) solution and added to a
solution of 10% fatty acid-free BSA (Sigma) that was
pre-warmed to 55 °C. The fatty acid-BSA conjugates
were mixed at 55 °C for 20 min then filter sterilized
through 0.45 μm syringe filters (Millipore, Billerica, MA)
and stored at − 20 °C in glass vials.
Cell culture
L6 myoblasts (1 × 105; passage 3–10) (ATCC, Manassas,
VA) were seeded in six-well culture plates in DMEM
(Gibco) containing 10% FBS (Atlas Biologicals, Fort
Collins, CO) and 1% Pen/Strep (Gibco). When the L6
myoblasts reached 80–85% confluence (approximately
48 h post seeding) they were induced to differentiate to
myotubes by replacing the media with DMEM contain-
ing 2% horse serum (Sigma) and 1% Pen/Strep (differen-
tiation media (DM)). DM was refreshed every 48 h. At
the end of the sixth day, fresh DM was added approxi-
mately 16 h prior to the addition of fatty acids, C6
ceramide (d18:1/6:0) (Avanti Polar Lipids, Alabaster,
Alabama), or chemical inhibitors of de novo ceramide
biosynthesis (myriocin) or PP2A (okadaic acid). For
experiments using chemical inhibitors, L6 myotubes
were pretreated for two hours with 50 nM myriocin
(Sigma), 15 nM okadaic acid (LC Labs, Woburn, MA),
or vehicle (methanol or DMSO, respectively) prior to
the addition of 150 μM fatty acid-BSA conjugate or
20 μM C6 ceramide. Cells were treated with fatty
acid-BSA conjugate or C6 ceramide for 24 h and
collected for analysis eight days after the onset of
differentiation.
Western blot analysis
L6 myotubes were washed once in cold phosphate buff-
ered saline and harvested in lysis buffer as described
previously [36]. Myotube samples were fractionated by
SDS-PAGE using Bio-Rad precast Criterion gels (Bio-
Rad, Hercules, CA) as previously described [37]. Select
PVDF membranes were stained with a reversible protein
stain kit according to the manufacturer’s instructions
(Pierce, Thermo Fisher). Primary antibodies against
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phospho-Akt (S473) (#4060; 1:2000), ERK1/2 (T202/
Y204) (#9101; 1:1000), and GSK3β (S9) (#5558; 1:1000),
and total-Akt (#9272; 1:1000), ERK1/2 (#9102; 1:1000),
and GSK3β (#12456; 1:1000) were purchased from Cell
Signaling (Danvers, MA). Anti-TNNT3 antibody
(#JLT12; 0.2 μg/mL) was purchased from Developmental
Studies Hybridoma Bank (Iowa City, IA). Western blot
densitometry was quantitated using Image J Software
(National Institutes of Health). Densitometry was
normalized to a pooled sample of untreated myotubes
collected in lysis buffer as above and run in duplicate on
each gel.
Tnnt3 splice form characterization and quantification
L6 myotubes were collected in 1 mL TRIzol then stored
at − 80 °C until total RNA was extracted per manufac-
turer’s instructions (Invitrogen, Thermo Fisher), with the
exception that the precipitated RNA pellet underwent an
additional 85% ethanol wash. One μg of total RNA was
reverse transcribed to cDNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Thermo Fisher). PCR was used to amplify Tnnt3 ampli-
cons representing all expressed splice forms as described
previously [36]. Fluorescein (6FAM)-labeled Tnnt3 PCR
products were diluted 1:10 and one μL per sample was
analyzed by capillary electrophoresis as described previ-
ously [36]. Briefly, separated Tnnt3 amplicons were
detected as individual fluorescence peaks of varying
height within a range of 0-1200 bp. An internal size
standard allowed accurate sizing of Tnnt3 amplicons
that were determined to vary between ~ 700-800 bp. The
relative abundance of each Tnnt3 amplicon was then cal-
culated by dividing the fluorescence peak height by the
total of all Tnnt3 amplicon peak heights. The fold
change in the relative abundance of each Tnnt3 splice
form relative to controls was calculated for each
experiment.
Quantitative real-time PCR of Tnnt3 mRNA
Quantitative real-time PCR (qRT-PCR) was performed
using the QuantStudio 12 K Flex Real-Time PCR System
and SYBR Green master mix (Qiagen, Germantown,
MD) according to the manufacturer’s instructions. Tnnt3
gene expression was quantified using rat specific primers
designed to constitutively expressed (i.e., not alterna-
tively spliced) Tnnt3 exons 11 and 12 (Fwd: 5’ GTCA
GAACAAGGACCTCATGG 3′, Rev.: 5’ TCTCAGCGC
GAATCCTTTG 3′) and a region within the gene Gapdh
(Fwd: 5’-AGTTCAACGGCACAGTCAAG-3′, Rev.: 5’-T
ACTCAGCACCAGCATCACC-3′). Changes in Tnnt3
gene expression were normalized to Gapdh using the
2−ΔΔCT method as described previously [38].
Statistical analysis
Tnnt3 splice form and Western blot analyses are
displayed as the mean fold change ± SEM of the relative
abundance or ratio of phosphorylated/total protein,
respectively, compared to controls. Fold change values
were calculated from each of three independent experi-
ments with three replicates per experiment. GraphPad
Prism v7.0 was used to generate graphs and to perform
Student’s t-tests or One- or Two-way ANOVA with
Fisher’s LSD post-hoc test for multiple comparisons to
determine statistical significance (p ≤ 0.05).
Results
Characterization of L6 myotube Tnnt3 splice form
expression
Skeletal muscle contractile elements, including Tnnt3,
are expressed in differentiated mouse (C2C12) myotubes
[36, 39], but to our knowledge a comprehensive analysis
of Tnnt3 splice forms had not been performed previ-
ously in rat L6 myotubes. Thus, we induced L6 myo-
blasts to differentiate into myotubes and analyzed Tnnt3
total mRNA, protein, and splice form expression at day
0 (D0), and day 8 (D8) post-differentiation onset. Myo-
blasts fused to form mature myotubes (Fig. 1a) and total
Tnnt3 mRNA abundance, as assessed by qRT-PCR, was
increased 76-fold by D8 (Fig. 1b). A similar effect was
observed with TNNT3 protein expression (Fig. 1c).
Capillary electrophoresis of Tnnt3 PCR amplicons
detected three Tnnt3 splice forms present in low abun-
dance at D0 (Fig. 1d). Expression of all three splice
forms present in undifferentiated myoblasts increased
after differentiation, and 15 splice forms not detected in
myoblasts were present in D8 myotubes (Fig. 1e).
In vitro modulation of Tnnt3 alternative splicing by fatty
acids and ceramides
We next tested if exposure to fatty acids could modulate
alternative splicing of Tnnt3 in L6 myotubes. Cells were
treated with BSA conjugated to saturated (palmitate),
mono- (oleate) and poly-unsaturated (linoleate) fatty
acids that were also present in the diets of our previous
study [19], or with BSA alone for 24 h. Treatment with
oleate or linoleate significantly altered the expression of
the 781 and 795 bp Tnnt3 splice forms compared to
BSA-treated myotubes, however the magnitude of the
effect was small (i.e., 1.2-fold or less; Table 1). The splice
form exhibiting the largest change was the 737 bp Tnnt3
splice form in response to palmitate treatment. This
effect was specific to palmitate as it caused a 1.8-fold in-
crease in relative abundance compared to treatment with
BSA alone while neither oleic nor linoleic acid treatment
had any effect on its relative abundance (Fig. 2a and
Table 1). The 737 bp Tnnt3 splice form was the most
consistently and robustly changed splice form across
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Fig. 1 Characterization of Tnnt3 mRNA, protein, and splice form expression in differentiating L6 myotubes. L6 myotubes were collected at the
onset of differentiation (D0) or eight days post differentiation (D8) as described in Methods. (a) Micrograph of D8 L6 myotubes. (b) Tnnt3 mRNA
abundance was assessed by qRT-PCR and normalized to Gapdh. (c) TNNT3 protein expression was assessed by Western blot analysis. Protein
staining of the Western blot membrane is shown to demonstrate equal protein loading. Capillary electrophoresis tracings of Tnnt3 splice forms
from (d) D0 or (e) D8 of differentiation as assessed by fragment analysis of Tnnt3 PCR amplicons. Black and gray tracings represent Tnnt3 splice
forms and internal size standards, respectively. Peak height is proportional to the splice form relative abundance. Data in (b) are presented as
means ± SEM from three independent experiments using three replicates per time point. Statistically different means as assessed by Student’s
t-test are denoted with an asterisk (*) (p≤ 0.05)
Table 1 Fold change in the relative abundance of Tnnt3 splice forms
Tnnt3 splice form size (bp) BSA PA OA LA
710 1.00 a 1.228 ± 0.240 a 1.042 ± 0.099 a 1.091 ± 0.067 a
725 1.00 a, c 1.212 ± 0.109 a 0.970 ± 0.041 b, c 1.022 ± 0.078 a, c
728 1.00 a 0.713 ± 0.098 a 0.832 ± 0.239 a 0.875 ± 0.270 a
737 1.00 a 1.851 ± 0.143 b 0.943 ± 0.053 a 0.921 ± 0.180 a
739 1.00 a 1.438 ± 0.202 a 1.327 ± 0.350 a 1.115 ± 0.403 a
742 1.00 a 1.026 ± 0.057 a 0.946 ± 0.044 a 0.978 ± 0.117 a
751 1.00 a 1.198 ± 0.209 a 0.662 ± 0.247 a 0.794 ± 0.063 a
754 1.00 a, b 1.233 ± 0.177 a 0.764 ± 0.150 b 0.826 ± 0.069 b
757 1.00 a 1.105 ± 0.061 a 0.923 ± 0.091 a 1.013 ± 0.086 a
763 1.00 a 0.989 ± 0.104 a 0.860 ± 0.097 a 0.884 ± 0.069 a
769 1.00 a 1.071 ± 0.036 a 0.906 ± 0.124 a 0.804 ± 0.112 a
775 1.00 a 1.334 ± 0.177 a 0.990 ± 0.233 a 0.977 ± 0.254 a
778 1.00 a 0.999 ± 0.164 a 1.151 ± 0.017 a 1.085 ± 0.119 a
781 1.00 a 0.950 ± 0.030 a 1.104 ± 0.014 b 1.114 ± 0.033 b
790 1.00 a 0.839 ± 0.070 a 0.833 ± 0.042 a 0.790 ± 0.157 a
793 1.00 a 0.837 ± 0.036 b, c 0.935 ± 0.054 a, c 0.776 ± 0.078 b
795 1.00 a, b 0.953 ± 0.044 a 1.071 ± 0.043 b 1.216 ± 0.078 c
807 1.00 a 0.966 ± 0.030 a, b 0.955 ± 0.035 a, b 0.909 ± 0.020 b
L6 myotubes were treated for 24 h with 150 μM palmitate, oleate, or linoleate (PA, OA, LA, respectively) conjugated to BSA or an equal volume of BSA alone. The
fold change in the relative abundance of Tnnt3 splice forms was assessed by capillary electrophoresis. Data are presented as means ± SEM from three
independent experiments using three replicates per treatment. Statistical significance was assessed by One-way ANOVA and Fishers LSD post-hoc test for multiple
comparisons. Statistically different means are denoted with different letters (p ≤ 0.05)
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studies. Moreover, the most abundant splice form in
adult rat loading bearing muscle, i.e. the gastrocnemius,
is the 737 bp splice form [34]. Therefore, for ease of
presentation, from here onward data for all 18 Tnnt3
splice forms will be presented in table format as Add-
itional Files and data for the 737 bp Tnnt3 splice form
will be presented in graphical format.
Palmitate is a substrate for serine palmitoyltransferase,
the initial and rate limiting step in de novo ceramide
biosynthesis [40]. Thus, the palmitate-induced effects on
Tnnt3 alternative splicing may be due to de novo biosyn-
thesis of ceramides. Indeed, a 24-h treatment with 20
μM C6 ceramide increased the relative abundance of the
737 bp Tnnt3 splice form by 2.7-fold (Fig. 2b and
Additional file 1). Additionally, C6 ceramide treatment
significantly altered the relative abundance of 6 of the 18
Tnnt3 splice forms (Additional file 1). Pre-treatment
with myriocin, a selective serine palmitoyltransferase
inhibitor which blocks the initial, crucial catalytic step of
ceramide biosynthesis, attenuated the palmitate-induced
increase in the relative abundance of the 737 bp Tnnt3
splice form (Fig. 2c and Additional file 2). These data
demonstrate that both fatty acids and ceramides induce
changes in Tnnt3 alternative splicing and that the effect
of palmitate likely requires de novo ceramide synthesis.
In vitro modulation of Akt S473 phosphorylation by fatty
acids and ceramides
We next sought to gain insight into possible signaling path-
ways involved in the palmitate- and ceramide-induced
a b c
Fig. 2 Fatty acid- and C6 ceramide-induced changes in Tnnt3 pre-mRNA alternative splicing. L6 myotubes were treated for 24 h with (a) 150 μM
palmitate, oleate, or linoleate (PA, OA, LA, respectively) conjugated to BSA or an equal volume of BSA alone, (b) 20 μM C6 ceramide (C6) or an equal
volume of methanol (Vehicle), or (c) 50 nM myriocin or an equal volume of methanol (Vehicle) for two hours prior to a 24-h treatment with 150 μM PA
bound to BSA (PA) or an equal volume of BSA alone. The fold change in the relative abundance of the 737 base pair Tnnt3 splice form was assessed
by capillary electrophoresis. Data are presented as means ± SEM from three independent experiments using three replicates per treatment. Statistical
significance was assessed by Student’s t-test (b) and One- and Two-way ANOVA with Fishers LSD post-hoc test for multiple comparisons (a and c,
respectively). Statistically different means are denoted with an asterisk (*) or different letters above the bars (p≤ 0.05)
a b c
Fig. 3 Fatty acid- and C6 ceramide-induced changes in Akt S473 phosphorylation. L6 myotubes were treated for 24 h with (a) 150 μM palmitate,
oleate, or linoleate (PA, OA, LA, respectively) conjugated to BSA or an equal volume of BSA alone, (b) 20 μM C6 ceramide (C6) or an equal volume
of methanol (Vehicle), or (c) 50 nM myriocin or an equal volume of methanol (Vehicle) for two hours prior to a 24-h treatment with 150 μM PA
bound to BSA or an equal volume of BSA alone. The ratio of phosphorylated Akt at S473 to total Akt was assessed by Western blot analysis. Black
lines in the Western blot images shown in B represent noncontiguous lanes from the same blot. Data are presented as means ± SEM from three
independent experiments using three replicates per treatment. Statistical significance was assessed by Student’s t-test (b) and One- and Two-way
ANOVA with Fishers LSD post-hoc test for multiple comparisons (a and c, respectively). Statistically different means are denoted with an asterisk
(*) or different letters above the bars (p≤ 0.05)
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effects on Tnnt3 alternative splicing. Therefore, we
assessed whether Akt signaling correlated with
changes to the relative abundance of the 737 bp Tnnt3
splice form because a hallmark effect of ceramides is
their ability to alter Akt phosphorylation [23, 41] and
our previous findings in C2C12 myotubes suggested
an important role for Akt in modulating Tnnt3
pre-mRNA alternative splicing [36]. As shown in
Fig. 3a, palmitate, but not oleate or linoleate, reduced
Akt S473 phosphorylation compared to BSA-treated
L6 myotubes (Fig. 3a). Moreover, treatment with C6
ceramide reduced Akt S473 phosphorylation by 39.5 ±
5.6%, compared to controls (Fig. 3b). Interestingly,
although palmitate treatment significantly reduced
Akt S473 phosphorylation, pretreatment with myrio-
cin did not prevent the palmitate-induced reduction
(Fig. 3c), suggesting that palmitate is either not acting
through Akt or acts downstream of Akt to modulate
alternative splicing.
Inhibition of PP2A attenuates the palmitate-and
ceramide-induced alternative splicing of Tnnt3
A major mode of action of ceramides is the activation of
PP1 and PP2A [16, 41]. Because changes in Akt S473
phosphorylation, a PP1 specific site [42], did not explain
the palmitate-induced effects on Tnnt3 alternative spli-
cing, we hypothesized that palmitate and C6 ceramide
exert their effects on Tnnt3 alternative splicing in part
through the activation of PP2A. A previous study [43]
showed that 15 nM okadaic acid selectively inhibited
PP2A in primary cultures of rat hepatocytes. Confirming
that finding, we found that in L6 myotubes, 15 nM
okadaic acid significantly increased the phosphorylation
of the PP2A substrates GSK-3β [44] and ERK1/2 [45]
but not the PP1 substrate Akt S473 (Fig. 4a-c). Notably,
pretreatment with 15 nM okadaic acid blocked the effect
of palmitate and C6 ceramide on the abundance of the
737 bp Tnnt3 splice form (Fig. 4d and e) and prevented
or attenuated the change in abundance of several other
a
d e
b c
Fig. 4 Palmitate- and C6 ceramide-induced changes in Tnnt3 pre-mRNA alternative splicing are blocked by inhibition of PP2A. a-c L6 myotubes
were pretreated for two hours with either 1 or 15 nM okadaic acid (OKA) or an equal volume of MeOH or DMSO for 24-h prior to Western blot
analysis. The ratio of (a) GSK3β at S9 to total GSK3β, (b) ERK1/2 at T202/Y204 to total ERK1/2, and (c) phosphorylated Akt at S473 to total Akt was
assessed. L6 myotubes were pretreated for two hours with okadaic acid or an equal volume of DMSO (Vehicle) prior to a 24-h treatment with (d)
150 μM PA conjugated to BSA (PA) or an equal volume of BSA alone or (e) 20 μM C6 ceramide (C6) or an equal volume of methanol (MeOH). The
fold change in the relative abundance of the 737 base pair Tnnt3 splice form was assessed by capillary electrophoresis (d and e). Data are
presented as means ± SEM from three independent experiments using three replicates per treatment. Statistical significance was assessed by
Student’s t-test (a-c) or Two-way ANOVA with Fishers LSD post-hoc test for multiple comparisons (d and e). Statistically different means are
denoted with an asterisk (*) or different letters above the bars (p≤ 0.05). # p = 0.08 vs. BSA/Vehicle
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Tnnt3 splice forms (Additional files 3 and 4). Thus,
these data suggest that the effects of palmitate and C6
ceramide on the alternative splicing of the 737 bp Tnnt3
splice form expression occurs in a PP2A-dependent
manner.
Discussion
The results of the present study support a model in
which saturated fatty acids increase ceramide expression
leading to the activation of PP2A and subsequent
changes in the alternative splicing of Tnnt3 pre-mRNA
in L6 myotubes. In support of this model, the data show
that both palmitate and C6 ceramide promote accumula-
tion of the 737 bp Tnnt3 splice form and that the effect
of palmitate is blocked by the ceramide synthesis inhibi-
tor, myriocin. Although we did not measure ceramide
levels in this study, others have demonstrated a time-
and dose-dependent increase in ceramide accumulation
in palmitate-treated cells in culture [46] and that the
increase is blocked by myriocin treatment [20]. Thus,
the repressive effect of myriocin on palmitate-induced
Tnnt3 alternative splicing is consistent with the fatty
acid acting through a mechanism requiring increased
ceramide synthesis to produce changes in alternative
splicing. Importantly, previous studies have demon-
strated that increased ceramide production is associated
with changes in alternative splicing of pre-mRNAs other
than Tnnt3. For example, both TNFα and gemcitabine
have been reported to alter the pattern of pre-mRNA
alternative splicing of PKCβII, caspase 9, and Bcl-xL and
myriocin blocks the effect [23, 24], suggesting that, like
palmitate, TNFα and gemcitabine-induced changes in
alternative splicing require de novo ceramide synthesis.
In the present study, we also found that fatty acids of
varying saturation level elicit distinct patterns of Tnnt3
pre-mRNA alternative splicing. Notably, in several
instances, the pattern of Tnnt3 alternative splicing was
different in myotubes treated with the unsaturated fatty
acids oleate and linoleate, compared to those treated
with palmitate. For example, treatment with either oleate
or linoleate elicited differential effects on the expression
of the 793 and 795 bp Tnnt3 splice forms (Table 1). The
effect of oleate or linoleate is most likely independent
of increased ceramide production because, unlike
palmitate, they have no effect on ceramide production
or accumulation in skeletal muscle [47] or in cells in
culture [48–50]. Instead, it is possible that there are
ceramide-independent mechanisms that lead to varia-
tions in the Tnnt3 splice form expression in response
to treatment with unsaturated fatty acids. However,
the magnitude of the changes in alternative splicing
induced by unsaturated fatty acids was small, and the
physiological significance of such relatively small
changes must be questioned.
An important mechanism for regulating alternative
splicing involves changes in phosphorylation of the SR
proteins that belong to the non-small nuclear ribonu-
cleoprotein particle splicing factor family of proteins [4,
11–14]. The SR proteins are phosphorylated on multiple
serine residues by various kinases including Akt, leading
to changes in the alternative splicing process [12, 14]. In
the present study, Akt phosphorylation on S473 was
reduced in response to treatment with either palmitate
or C6 ceramide in association with increased Tnnt3 737
abundance, consistent with a possible role for altered
Akt signaling in mediating the observed changes in
alternative splicing. However, although myriocin blocked
the palmitate-induced changes in alternative splicing, it
did not prevent the changes in Akt S473 phosphoryl-
ation, suggesting that the changes in alternative splicing
occurred in an Akt-independent manner. Instead,
okadaic acid when used at a concentration that in-
hibits PP2A but not PP1 blocked the effect of both
palmitate and ceramide on alternative splicing of the
Tnnt3 737 splice form. Previous studies have shown
that ceramide treatment leads to activation of both
PP1 and PP2A [51–53]. Thus, it is tempting to specu-
late that palmitate-induced ceramide production leads
to activation of PP2A and subsequent modulation of
Tnnt3 alternative splicing.
It is interesting that treatment with C6 ceramide
had a more dramatic effect on Tnnt3 alternative spli-
cing compared to palmitate, both with regard to the
number of splice forms affected and, in some cases,
the magnitude of the change. Although the basis for
this difference is unknown, it is noteworthy that C6
ceramide is cell permeable and does not need to be
bound to BSA to be soluble in aqueous solution [24].
In contrast, palmitate was bound to BSA and requires
fatty acid transport proteins to enter the cell [54].
Thus, C6 ceramide likely enters the cell more rapidly
compared to palmitate, and may reach higher intra-
cellular concentrations more quickly compared to the
ceramide generated by palmitate-induced increases in
synthesis. It is also possible that the shorter chain
ceramides like C6 ceramide have a differential effect
to promote alternative splicing compared to longer
chain ones.
Conclusion
In addition to acting as energy sources and structural
components of cells, fatty acids and their metabolites act
as signaling molecules to regulate gene expression. The
data presented in the current study extend the biological
significance of fatty acids by demonstrating that fatty
acids and their metabolites play a role in the selection of
exons for alternative splicing and uncover an important
node in the nutrient control of gene expression. The
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basic mechanisms of pre-mRNA alternative splicing have
been studied extensively [10, 55]. However, surprisingly,
how alternative splicing regulatory mechanisms are
influenced by changes in environmental conditions or
nutrient availability has only recently been investigated
[19, 56, 57]. Approximately 95% of all multi-exon
pre-mRNAs are thought to generate multiple mature
mRNA splice forms [3], therefore future studies should
expand upon the list of pre-mRNAs affected by nutrient
availability, the signaling pathways involved, and the
functional outcomes of these changes.
Additional files
Additional file 1: Fold change in the relative abundance of Tnnt3 splice
forms in L6 myotubes treated with C6 ceramide. (DOCX 15 kb)
Additional file 2: Fold change in the relative abundance of Tnnt3 splice
forms in L6 myotubes treated with myriocin. (DOCX 16 kb)
Additional file 3: Fold change in the relative abundance of Tnnt3
splice forms in L6 myotubes treated with okadaic acid and palmitate.
(DOCX 16 kb)
Additional file 4: Fold change in the relative abundance of Tnnt3
splice forms in L6 myotubes treated with okadaic acid and C6
ceramide. (DOCX 16 kb)
Abbreviations
Bcl-xL: B-cell lymphoma extra-long; bp: base pairs; BSA: bovine serum
albumin; DM: differentiation medium; ERK: extracellular signal-regulated kin-
ase; GSK3β: glycogen synthase kinase 3β; LA: linoleic acid; OA: oleic acid;
PA: palmitic acid; PP: protein phosphatase; SR: serine-arginine-rich;
TNFα: tumor necrosis factor α; Tnnt3: troponin T3
Acknowledgements
We gratefully acknowledge Holly Lacko and Lydia Kutzler for their technical
assistance in performing portions of the studies described in this manuscript
and Dr. Leonard S. Jefferson for critical reading of the manuscript.
Funding
This research was supported by NIH grant R01-DK-09141 (to SRK) and NSF
grant IOS 1457237 (to RJS).
Availability of data and materials
All data generated or analyzed during this study are included in this published
article [and its supplementary information files].
Authors’ contributions
AJB and SRK designed experiments, AJB performed experiments and wrote
the manuscript, RJS and SRK participated in manuscript preparation. All
authors have approved the final version of the manuscript.
Ethics approval and consent to participate
Not applicable (no humans or animals).
Consent for publication
All authors consent to publication of the data.
Competing interests
The authors declare they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Cellular and Molecular Physiology, Penn State College of
Medicine, H166, 500 University Drive, Hershey, PA 17033, USA. 2Present
Address: Department of Cell Biology and Physiology, 6330 Medical
Biomolecular Research Building, 111 Mason Farm Rd, Chapel Hill, NC 27599,
USA. 3Department of Entomology and Biology, Penn State University,
University Park, PA, USA.
Received: 22 August 2018 Accepted: 10 December 2018
References
1. Baralle FE, Giudice J. Alternative splicing as a regulator of development and
tissue identity. Nat Rev Mol Cell Biol. 2017;18:437–51.
2. Bortfeldt R, Schindler S, Szafranski K, Schuster S, Holste D. Comparative
analysis of sequence features involved in the recognition of tandem splice
sites. BMC Genomics. 2008;9:202.
3. Lee Y, Rio DC. Mechanisms and regulation of alternative pre-mRNA splicing.
Annu Rev Biochem. 2015;84:291–323.
4. Naro C, Sette C. Phosphorylation-mediated regulation of alternative splicing
in cancer. Int J Cell Biol. 2013;2013:151839.
5. Castle JC, Zhang C, Shah JK, Kulkarni AV, Kalsotra A, Cooper TA, Johnson JM.
Expression of 24,426 human alternative splicing events and predicted cis
regulation in 48 tissues and cell lines. Nat Genet. 2008;40:1416–25.
6. Matera AG, Wang Z. A day in the life of the spliceosome. Nat Rev Mol Cell
Biol. 2014;15:108–21.
7. Szeszel-Fedorowicz W, Talukdar I, Griffith BN, Walsh CM, Salati LM. An exonic
splicing silencer is involved in the regulated splicing of glucose 6-
phosphate dehydrogenase mRNA. J Biol Chem. 2006;281:34146–58.
8. Bland CS, Wang ET, Vu A, David MP, Castle JC, Johnson JM, Burge CB,
Cooper TA. Global regulation of alternative splicing during myogenic
differentiation. Nucleic Acids Res. 2010;38:7651–64.
9. Huelga SC, Vu AQ, Arnold JD, Liang TY, Liu PP, Yan BY, Donohue JP, Shiue L,
Hoon S, Brenner S, et al. Integrative genome-wide analysis reveals cooperative
regulation of alternative splicing by hnRNP proteins. Cell Rep. 2012;1:167–78.
10. Sebbag-Sznajder N, Raitskin O, Angenitzki M, Sato TA, Sperling J, Sperling R.
Regulation of alternative splicing within the supraspliceosome. J Struct Biol.
2012;177:152–9.
11. Sanidas I, Polytarchou C, Hatziapostolou M, Ezell SA, Kottakis F, Hu L, Guo A, Xie J,
Comb MJ, Iliopoulos D, Tsichlis PN. Phosphoproteomics screen reveals akt isoform-
specific signals linking RNA processing to lung cancer. Mol Cell. 2014;53:577–90.
12. Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H, Hu Q, Ghosh G, Adams JA,
Rosenfeld MG, Fu XD. The Akt-SRPK-SR axis constitutes a major pathway in
transducing EGF signaling to regulate alternative splicing in the nucleus.
Mol Cell. 2012;47:422–33.
13. Zhu C, Yin Z, Tan B, Guo W. Insulin regulates titin pre-mRNA splicing
through the PI3K-Akt-mTOR kinase axis in a RBM20-dependent manner.
Biochim Biophys Acta. 2017;1863:2363–71.
14. Blaustein M, Pelisch F, Tanos T, Munoz MJ, Wengier D, Quadrana L, Sanford
JR, Muschietti JP, Kornblihtt AR, Caceres JF, et al. Concerted regulation of
nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol.
2005;12:1037–44.
15. Shi Y, Reddy B, Manley JL. PP1/PP2A phosphatases are required for the
second step of pre-mRNA splicing and target specific snRNP proteins. Mol
Cell. 2006;23:819–29.
16. Chalfant CE, Ogretmen B, Galadari S, Kroesen BJ, Pettus BJ, Hannun YA. FAS
activation induces dephosphorylation of SR proteins; dependence on the
de novo generation of ceramide and activation of protein phosphatase 1. J
Biol Chem. 2001;276:44848–55.
17. Michlewski G, Sanford JR, Caceres JF. The splicing factor SF2/ASF regulates
translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell.
2008;30:179–89.
18. Johnston JR, Chase PB, Pinto JR. Troponin through the looking-glass:
emerging roles beyond regulation of striated muscle contraction.
Oncotarget. 2018;9:1461–82.
19. Black AJ, Ravi S, Jefferson LS, Kimball SR, Schilder RJ. Dietary fat quantity and
type induce transcriptome-wide effects on alternative splicing of pre-mRNA
in rat skeletal muscle. J Nutr. 2017;147:1648–57.
20. Miklosz A, Lukaszuk B, Baranowski M, Gorski J, Chabowski A. Effects of inhibition
of serine palmitoyltransferase (SPT) and sphingosine kinase 1 (SphK1) on
palmitate induced insulin resistance in L6 myotubes. PLoS One. 2013;8:e85547.
Black et al. Nutrition & Metabolism           (2018) 15:87 Page 8 of 9
21. Blachnio-Zabielska AU, Chacinska M, Vendelbo MH, Zabielski P. The crucial
role of C18-Cer in fat-induced skeletal muscle insulin resistance. Cell Physiol
Biochem. 2016;40:1207–20.
22. Nikolova-Karakashian MN, Reid MB. Sphingolipid metabolism, oxidant
signaling, and contractile function of skeletal muscle. Antioxid Redox Signal.
2011;15:2501–17.
23. Ghosh N, Patel N, Jiang K, Watson JE, Cheng J, Chalfant CE, Cooper DR.
Ceramide-activated protein phosphatase involvement in insulin resistance
via Akt, serine/arginine-rich protein 40, and ribonucleic acid splicing in L6
skeletal muscle cells. Endocrinology. 2007;148:1359–66.
24. Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B,
Hannun YA. De novo ceramide regulates the alternative splicing of caspase
9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein
phosphatase-1. J Biol Chem. 2002;277:12587–95.
25. Brandimarti P, Costa-Junior JM, Ferreira SM, Protzek AO, Santos GJ, Carneiro
EM, Boschero AC, Rezende LF. Cafeteria diet inhibits insulin clearance by
reduced insulin-degrading enzyme expression and mRNA splicing. J
Endocrinol. 2013;219:173–82.
26. Kim Y, Tamura T, Iwashita S, Tokuyana K, Suzuki M. Effect of high-fat diet on
gene expression of GLUT4 and insulin receptor in soleus muslce. Biochem
Biophys Res Commun. 1994;202:519–26.
27. Marden JH, Fescemyer HW, Saastamoinen M, MacFarland SP, Vera JC,
Frilander MJ, Hanski I. Weight and nutrition affect pre-mRNA splicing of a
muscle gene associated with performance, energetics and life history. J Exp
Biol. 2008;211:3653–60.
28. Tao H, Szeszel-Fedorowicz W, Amir-Ahmady B, Gibson MA, Stabile LP, Salati
LM. Inhibition of the splicing of glucose-6-phosphate dehydrogenase
precursor mRNA by polyunsaturated fatty acids. J Biol Chem. 2002;277:
31270–8.
29. Walsh CM, Suchanek AL, Cyphert TJ, Kohan AB, Szeszel-Fedorowicz W, Salati
LM. Serine arginine splicing factor 3 is involved in enhanced splicing of
glucose-6-phosphate dehydrogenase RNA in response to nutrients and
hormones in liver. J Biol Chem. 2013;288:2816–28.
30. Griffith BN, Walsh CM, Szeszel-Fedorowicz W, Timperman AT, Salati LM.
Identification of hnRNPs K, L and A2/B1 as candidate proteins involved in
the nutritional regulation of mRNA splicing. Biochim Biophys Acta. 2006;
1759:552–61.
31. Kaminska D, Hämäläinen M, Cederberg H, Käkelä P, Venesmaa S, Miettinen
P, Ilves I, Herzig KH, Kolehmainen M, Karhunen L, et al. Adipose tissue INSR
splicing in humans associates with fasting insulin level and is regulated by
weight loss. Diabetologia. 2014;57:347–51.
32. Kaminska D, Kuulasmaa T, Venesmaa S, Käkelä P, Vaittinen M, Pulkkinen L,
Pääkkönen M, Gylling H, Laakso M, Pihlajamäki J. Adipose tissue TCF7L2
splicing is regulated by weight loss and associates with glucose and fatty
acid metabolism. Diabetes. 2012;61:2807–13.
33. Kaminska D, Pihlajamaki J. Regulation of alternative splicing in obesity and
weight loss. Adipocyte. 2013;2:143–7.
34. Schilder RJ, Kimball SR, Marden JH, Jefferson LS. Body weight-dependent
troponin T alternative splicing is evolutionarily conserved from insects to
mammals and is partially impaired in skeletal muscle of obese rats. J Exp
Biol. 2011;214:1523–32.
35. Webster NJG, Huang Z. Hormonal regulation of alternative splicing. In:
Chew SL, editor. Post-transcriptional processing and the endocrine system.
New York: Karger; 1999. p. 1–17.
36. Schilder RJ, Kimball SR, Jefferson LS. Cell-autonomous regulation of fast
troponin T pre-mRNA alternative splicing in response to mechanical stretch.
Am J Physiol Cell Physiol. 2012;303:C298–307.
37. Black AJ, Gordon BS, Dennis MD, Jefferson LS, Kimball SR. Regulation of
protein and mRNA expression of the mTORC1 repressor REDD1 in response
to leucine and serum. Biochem Biophys Rep. 2016;8:296–301.
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods.
2001;25:402–8.
39. Cabane C, Englaro W, Yeow K, Ragno M, Derijard B. Regulation of C2C12
myogenic terminal differentiation by MKK3/p38a pathway. Am J Physiol Cell
Physiol. 2003;284:C658–C66.
40. Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ, Hannun YA. Serine
Palmitoyltransferase regulates de novo ceramide generation during
etoposide-induced apoptosis. J Biol Chem. 2000;275:9078–84.
41. Mahfouz R, Khoury R, Blachnio-Zabielska A, Turban S, Loiseau N, Lipina C,
Stretton C, Bourron O, Ferre P, Foufelle F, et al. Characterising the inhibitory
actions of ceramide upon insulin signaling in different skeletal muscle cell
models: a mechanistic insight. PLoS One. 2014;9:e101865.
42. Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L.
The heat shock protein 90 inhibitor Geldanamycin and the ErbB inhibitor
ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in
ErbB2 overexpressing breast Cancer cells. Cancer Res. 2003;63:7777–84.
43. Holen I, Gordon PB, Seglen PO. Inhibition of hepatocytic autophagy by
okadaic acid and other protein phosphatase inhibitors. Eur J Biochem. 1993;
215:113–22.
44. Hernandez F, Langa E, Cuadros R, Avila J, Villanueva N. Regulation of GSK3
isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem. 2010;344:211–5.
45. Liu Q, Hofmann PA. Protein phosphatase 2A-mediated cross-talk between
p38 MAPK and ERK in apoptosis of cardiac myocytes. Am J Physiol Heart
Circ Physiol. 2004;286:H2204–H12.
46. Watt MJ, Barnett AC, Bruce CR, Schenk S, Horowitz JF, Hoy AJ. Regulation of
plasma ceramide levels with fatty acid oversupply: evidence that the liver detects
and secretes de novo synthesised ceramide. Diabetologia. 2012;55:2741–6.
47. Thombare K, Ntika S, Wang X, Krizhanovskii C. Long chain saturated and
unsaturated fatty acids exert opposing effects on viability and function of
GLP-1-producing cells: mechanisms of lipotoxicity. PLoS One. 2017;12:
e0177605.
48. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S,
Knotts TA, Shui G, Clegg DJ, Wenk MR, et al. Lipid-induced insulin resistance
mediated by the proinflammatory receptor TLR4 requires saturated fatty
acid-induced ceramide biosynthesis in mice. J Clin Invest. 2011;121:1858–70.
49. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K,
Hoehn KL, Knotts TA, Siesky A, et al. Inhibition of ceramide synthesis
ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin
resistance. Cell Metab. 2007;5:167–79.
50. Zhang Y, Rao E, Zeng J, Hao J, Sun Y, Liu S, Sauter ER, Bernlohr DA, Cleary
MP, Suttles J, Li B. Adipose fatty acid binding protein promotes saturated
fatty acid-induced macrophage cell death through enhancing ceramide
production. J Immunol. 2017;198:798–807.
51. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates
heterotrimeric protein phosphatase 2A. J Biol Chem. 1993;268:15523–30.
52. Chalfant CE, Kishihawa K, Mumby MC, Kamibayashi C, Bielawska A, Hannun
YA. Long chain ceramides activate protein phosphatase-1 and protein
phosphatase-2A. J Biol Chem. 1999;274:20313–7.
53. Chalfant CE, Szulc Z, Roddy P, Bielawska A, Hannun YA. The structural
requirements for ceramide activation of serine-threonine protein
phosphatases. J Lipid Res. 2004;45:496–506.
54. Glatz JF, Luiken JJ. Fatty acids in cell signaling: historical perspective and
future outlook. Prostaglandins Leukot Essent Fatty Acids. 2015;92:57–62.
55. Will CL, Luhrmann R. Splicing of a rare class of introns by the U12-
dependent spliceosome. Biol Chem. 2005;386:713–24.
56. Guan Y, Liang G, Martin GB, Guan LL. Functional changes in mRNA
expression and alternative pre-mRNA splicing associated with the effects of
nutrition on apoptosis and spermatogenesis in the adult testis. BMC
Genomics. 2017;18:64.
57. Ravi S, Schilder RJ, Berg AS, Kimball SR. Effects of age and hindlimb
immobilization and remobilization on fast troponin T precursor mRNA
alternative splicing in rat gastrocnemius muscle. Appl Physiol Nutr Metab.
2016;41:142–9.
Black et al. Nutrition & Metabolism           (2018) 15:87 Page 9 of 9
